Transcatheter Aortic Prosthesis Function: A Long-term Follow-up Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Megan Rowland, MPH
- Phone Number: 202-877-2959
- Email: megan.e.rowland@medstar.net
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Recruiting
- Washington Hospital Center
-
Contact:
- Megan Rowland
- Phone Number: 202-877-2959
- Email: megan.e.rowland@medstar.net
-
Principal Investigator:
- Ron Waksman, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
This observational study will enroll subjects that underwent TAVR more than 3 years ago. TAVR.
Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
Description
Inclusion criteria for TAVR subjects
a) TAVR performed more than 3 years ago
Exclusion criteria
- Subjects unable to consent to participate, unless the subject has a legally authorized representative
- Subjects unwilling to participate
- Subject has undergone re-intervention to prosthetic aortic valve since TAVR procedure (e.g. balloon valvuloplasty, SAVR, re-do TAVR, paravalvular leak closure)
- Echocardiographic evidence of prosthetic valve dysfunction within first 3 years post-TAVR (mean aortic gradient ≥20mmHg AND/OR moderate-severe transvalvular aortic regurgitation)
Inclusion criteria for SAVR subjects
- SAVR performed more than 3 years ago
- Propensity matched to an enrolled TAVR subject
Exclusion criteria for SAVR subjects e) Subjects unable to consent to participate, unless the subject has a legally authorized representative f) Subjects unwilling to participate g) Subject has undergone re-intervention to prosthetic aortic valve since TAVR procedure (e.g. balloon valvuloplasty, SAVR, re-do TAVR, paravalvular leak closure) h) Echocardiographic evidence of prosthetic valve dysfunction within first 3 years post-SAVR (mean aortic gradient ≥20mmHg AND/OR moderate-severe transvalvular aortic regurgitation)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
TAVR
This observational study will enroll subjects that underwent TAVR more than 3 years ago.
|
subjects that underwent TAVR more than 3 years ago
|
|
SAVR
Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
|
Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prosthetic valve dysfunction
Time Frame: 7 years
|
Mean aortic valve gradient ≥20 mm Hg Moderate-severe transvalvular aortic regurgitation
|
7 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in functional status
Time Frame: discharge from hospital
|
Change in functional status from baseline and discharge per NYHA classification
|
discharge from hospital
|
|
Increase in severity of aortic regurgitation
Time Frame: upto 7 years
|
Increase in severity of aortic regurgitation by one or more grading of severity
|
upto 7 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- TAVR Durability
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Valve Replacement
-
NCT05404880Active, not recruitingAortic Valve Replacement
-
NCT04902053SuspendedAortic Valve Replacement
-
NCT02381678CompletedMitral Valve or Aortic Valve Replacement
-
NCT06782620CompletedAortic Valve Replacement
-
NCT03680040Terminated
-
NCT01554709CompletedAortic Valve Replacement
-
NCT02523066TerminatedMitral Valve or Aortic Valve Replacement
-
NCT07453849Not yet recruitingAortic Regurgitation | Transcatheter Aortic Valve Replacement
-
NCT03200574CompletedAortic-valve Replacement
-
NCT01522352UnknownAortic Valve Replacement
Clinical Trials on TAVR
-
NCT07278310RecruitingAortic Stenosis | Symptomatic Severe Native Aortic Stenosis
-
NCT05779787RecruitingAortic Valve Stenosis | Transcatheter Aortic Valve Replacement
-
NCT03222128CompletedSymptomatic Severe Aortic Stenosis
-
NCT04500964CompletedFailed Transcather Aortic Valve
-
NCT04734392CompletedPM Implantation After TAVR
-
NCT05721820Completed
-
NCT02184442CompletedCalcific Aortic Stenosis | Severe | Symptomatic
-
NCT03735667Active, not recruiting
-
NCT03056573Completed